Ovid Therapeutics News

Buy Rating for Ovid Therapeutics Based on Novel SE Drug Candidates OV329 and OV350

TipRanks05:55 ET

Express News | HC Wainwright & Co. Reiterates Buy on Ovid Therapeutics, Maintains $9 Price Target

BenzingaMay 16 07:07 ET

Buy Rating for Ovid Therapeutics Based on Promising Drug Trials and Strategic Partnerships

TipRanksMay 16 06:29 ET

TD Cowen Reaffirms Their Buy Rating on Ovid Therapeutics (OVID)

TipRanksMay 15 07:16 ET

Strong Buy: Ovid Therapeutics' Promising Pipeline and Financial Stability

TipRanksMay 15 06:12 ET

Ovid Therapeutics | 10-Q: Quarterly report

SEC announcementMay 14 08:14 ET · Announcements

Express News | Ovid Therapeutics Inc -Ovid Anticipates Its Cash Runway Will Support Operations and Clinical Development Programs Into H1 2026

ReutersMay 14 08:03 ET

Express News | Ovid Therapeutics Inc -Ovid Expects to Initiate a Phase 2 Clinical Program Studying Ov888 (Gv101) in Cerebral Cavernous Malformations in H2 2024

ReutersMay 14 08:03 ET

Ovid Therapeutics 1Q Rev $148,000 >OVID

Ovid Therapeutics 1Q Rev $148,000 >OVID

Dow JonesMay 14 08:02 ET

Express News | Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results

ReutersMay 14 08:00 ET

Express News | Ovid Therapeutics Q1 EPS USD -0.17 Vs. Ibes Estimate USD -0.22

ReutersMay 14 08:00 ET

Express News | Ovid Therapeutics Q1 Operating Expenses USD 17.565 Million

ReutersMay 14 08:00 ET

Express News | Ovid Therapeutics Q1 Net Income USD -11.694 Million

ReutersMay 14 08:00 ET

Express News | Ovid Therapeutics Q1 Basic EPS USD -0.17

ReutersMay 14 08:00 ET

Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by

GlobeNewswireMay 13 07:00 ET

Cracking The Code: Understanding Analyst Reviews For Ovid Therapeutics

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Ovid Therapeutics (NASDAQ:OVID) in the last three months.The following table summarizes their re

BenzingaMay 7 15:00 ET

Ovid Therapeutics Is Maintained at Neutral by Citigroup

Ovid Therapeutics Is Maintained at Neutral by Citigroup

Dow JonesMay 7 13:51 ET

Citigroup Maintains Neutral on Ovid Therapeutics, Lowers Price Target to $3.5

Citigroup analyst Yigal Nochomovitz maintains Ovid Therapeutics (NASDAQ:OVID) with a Neutral and lowers the price target from $4 to $3.5.

BenzingaMay 7 13:42 ET

Express News | Ovid Therapeutics Inc : Citigroup Cuts Target Price to $3.5 From $4

ReutersMay 7 07:10 ET

B. Riley Securities Initiates Ovid Therapeutics With Buy Rating, $9 Price Target

Ovid Therapeutics (OVID) has an average rating of buy and price targets ranging from $4 to $11, according to analysts polled by Capital IQ.

MT NewswiresApr 30 07:23 ET